Preclinical and clinical investigation of VES001, an oral small molecule sortilin receptor inhibitor for the treatment of frontotemporal dementia: a first-in-human randomized placebo-controlled phase 1 trial

Read full text Summarise with VIRAT
Authors: L. Klem, Daniel Dumas, Imogen J. Swift, Sofie L. Frandsen, Ditte Nedergaard Mikkelsen, Laerke Fensbaek, Yalcin Yavuz, Okke Merton, Jesminne Castricum, Simone Prichardt, Graham M. Wynne, Anders Riisager
+7 more Nina Schultz, Paul B Little, Ove Pedersen, Eva Thijssen, Anders Nykjær, Philip H. C. Kremer, Mads Kjølby
Cited by: 0
References: 47

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

GRN haploinsufficiency reduces progranulin and causes frontotemporal dementia (FTD-GRN). VES001, an oral small-molecule sortilin inhibitor, increases progranulin without downregulating sortilin. Preclinically, VES001 bound sortilin selectively and elevated progranulin in plasma, cerebrospinal fluid (CSF), and hippocampal interstitial fluid of male rats. In a randomized, double-blind, placebo-controlled first-in-human phase 1 A study, 79 healthy adults (63/37% male/female; mean age 28 years) received VES001 or placebo as single ascending doses (10-990 mg) or multiple ascending doses for 7 days (180 mg once or twice daily, or 450 mg twice daily). Safety and tolerability, the primary endpoints, were met: no deaths, serious adverse events or treatment-related discontinuations; headache and fatigue were mild and not dose-related. Pharmacokinetics were dose-proportional, with blood-brain barrier penetration. Prespecified pharmacodynamic endpoints were met as single dosing increased plasma progranulin, and twice-daily dosing produced greater, sustained increases versus placebo in plasma (peak 49% change from baseline) and CSF (18% change from baseline). Although cohorts were small, dosing lasted 7 days, and participants were healthy, these findings establish pharmacological proof of mechanism for oral sortilin inhibition and support further development of VES001 as a potential disease-modifying therapy for FTD-GRN. EU CTR 2023-505847-38-00; ClinicalTrials.gov NCT06226064.

Fields of Study & Subjects

Alzheimer's disease research and treatments Amyotrophic Lateral Sclerosis Research Dementia and Cognitive Impairment Research

Publication details

Journal / source
Nature Communications
Volume
17
Issue
1
Pages
10804
Publication date
14 September 2026
Language
EN